We serve Chemical Name:Chlorphenesin carbamate CAS:886-74-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Chlorphenesin carbamate
CAS.NO:886-74-8
Synonyms:Carbamic Acid 3-(p-Chlorophenoxy)-2-hydroxypropyl Ester;3-[(4-chlorophenyl)oxy]-2-hydroxypropyl carbamate;MFCD00072002;3-(4-Chlorophenoxy)-2-hydroxypropyl carbamate;Chlorphensin carbamate;1,2-Propanediol, 3-(4-chlorophenoxy)-, 1-carbamate;Maolate;Kolpicortin-sine;[3-(4-chlorophenoxy)-2-hydroxypropyl] carbamate;1,2-Propanediol-3-(p-chlorophenoxy)-1-carbamate;Rinlaxer;Chlorphenesin;Chlorphenesin carbamate;EINECS 212-954-7
Molecular Formula:C10H12ClNO4
Molecular Weight:245.660
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:481.8±40.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.564
PSA:81.78000
Exact Mass:245.045486
LogP:1.41
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Carbamic Acid 3-(p-Chlorophenoxy)-2-hydroxypropyl Ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 212-954-7 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Carbamic Acid 3-(p-Chlorophenoxy)-2-hydroxypropyl Ester Use and application,Carbamic Acid 3-(p-Chlorophenoxy)-2-hydroxypropyl Ester technical grade,usp/ep/jp grade.
Related News: This is how an API becomes a medicine. Chlorphenesin carbamate manufacturer ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy. Chlorphenesin carbamate supplier This is how an API becomes a medicine. Chlorphenesin carbamate vendor This is how an API becomes a medicine. Chlorphenesin carbamate factory ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.
